

Investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF- β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

INTR@PID[™] BREAST 020¹

Now Enrolling



METASTATIC
TNBC



PHASE
2



MONOTHERAPY

INTR@PID BREAST 020 (NCT04489940) is a phase 2, single-arm study evaluating bintrafusp alfa for the treatment of patients with metastatic triple-negative breast cancer (TNBC) that has high expression of *HMGA2*.*

Study design | Europe and the United States



Key inclusion criteria[‡]

- Participants must have histologically or cytologically confirmed TNBC with *HMGA2*-high* tumor expression and an ECOG PS of 0 or 1. Participants must have received prior systemic therapy for metastatic disease and experienced disease progression immediately prior to study entry


Key exclusion criteria[‡]

- Participants must not have received prior cancer treatment with any immunotherapy, immune checkpoint inhibitor, or immune-modulating monoclonal antibody

**HMGA2*-high tumor expression will be determined by a centralized RT-PCR test. [‡]Until confirmed progression, unacceptable toxicity, study withdrawal, or death. [†]For a full list of inclusion and exclusion criteria, please visit www.clinicaltrials.gov.

DOR, duration of response; DRR, durable response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; *HMGA2*, high mobility group AT-hook 2; IV, intravenous; OR, objective response; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q2W, every 2 weeks; RT-PCR, reverse transcriptase-polymerase chain reaction; TGF- β , transforming growth factor β ; TNBC, triple-negative breast cancer.

Reference: 1. ClinicalTrials.gov. Bintrafusp alfa in high mobility group AT-hook 2 (*HMGA2*) expressing triple negative breast cancer. <https://clinicaltrials.gov/ct2/show/NCT04489940>. Accessed February 4, 2021.



For more information, visit
www.intrapidclinicaltrials.com
www.clinicaltrials.gov